Robert Henry, MD

Robert Henry, MD

Chief, Center for Metabolic Research 
Chief, Section of Endocrinology, Metabolism & Diabetes
Veterans Affairs Healthcare System
Professor of Medicine‚ Department of Medicine
Division of Endocrinology and Metabolism
University of California‚ San Diego

Related Videos

What are we learning about the efficacy and safety of ultra-long-acting insulins such as degludec and U300 glargine? Video

What are we learning about the efficacy and safety of ultra-long-acting insulins such as degludec and U300 glargine?

What are we learning about the efficacy and safety of ultra-long-acting insulins such as degludec and U300 glargine?

What are the implications of the LEADER trial for practitioners at the front lines of diabetes care? And how will it fit into the treatment algorithm? Video

What are the implications of the LEADER trial for practitioners at the front lines of diabetes care? And how will it fit into the treatment algorithm?

What are the implications of the LEADER trial for practitioners at the front lines of diabetes care? And how will it fit into the treatment algorithm?

How do the results and study design of LEADER differ from the CV outcomes study that evaluated lixisenatide in patients with T2D? Was the CV protection seen in LEADER observed in diabetic patients on statins? How does LEADER differ from the EMPA-REG study? Video

How do the results and study design of LEADER differ from the CV outcomes study that evaluated lixisenatide in patients with T2D? Was the CV protection seen in LEADER observed in diabetic patients on statins? How does LEADER differ from the EMPA-REG study?

How do the results and study design of LEADER differ from the CV outcomes study that evaluated lixisenatide in patients with T2D? Was the CV protection seen in LEADER observed in diabetic patients on statins? How does LEADER differ from the EMPA-REG study?

What results from LEADER, showing CV risk reduction with liraglutide, do you think are most important and how are they likely to change our use of GLP-1 RAs in high risk patients with T2D? Video

What results from LEADER, showing CV risk reduction with liraglutide, do you think are most important and how are they likely to change our use of GLP-1 RAs in high risk patients with T2D?

What results from LEADER, showing CV risk reduction with liraglutide, do you think are most important and how are they likely to change our use of GLP-1 RAs in high risk patients with T2D?

Are there clinically relevant differences between the fixed ratio, combination regimens-- iGlarLixi or iDegLira--consisting of a long-acting insulin and GLP-1 RA? Video

Are there clinically relevant differences between the fixed ratio, combination regimens-- iGlarLixi or iDegLira--consisting of a long-acting insulin and GLP-1 RA?

Are there clinically relevant differences between the fixed ratio, combination regimens— iGlarLixi or iDegLira— consisting of a long-acting insulin and GLP-1 RA?

Why are the risks of hypoglycemia very low when using the fixed ratio, combination regimens? Does this have to do with slow titration or mechanistic complementarity? Video

Why are the risks of hypoglycemia very low when using the fixed ratio, combination regimens? Does this have to do with slow titration or mechanistic complementarity?

Why are the risks of hypoglycemia very low when using the fixed ratio, combination regimens? Does this have to do with slow titration or mechanistic complementarity? By what mechanism do they mitigate hypoglycemic risk?

Can you provide some discrete clinical and patient profiles where fixed ratio, combination regimens consisting of a long-acting insulin and GLP-1 RA should be strongly considered? Video

Can you provide some discrete clinical and patient profiles where fixed ratio, combination regimens consisting of a long-acting insulin and GLP-1 RA should be strongly considered?

Can you provide some discrete clinical and patient profiles where fixed ratio, combination regimens consisting of a long-acting insulin and GLP-1 RA should be strongly considered?

Which T2D patients will be the best candidates for the fixed ratio, combination regimens, i.e., iGlarLixi or iDegLira? And how effective and safe are these formulations at lowering HA1c levels? Video

Which T2D patients will be the best candidates for the fixed ratio, combination regimens, i.e., iGlarLixi or iDegLira? And how effective and safe are these formulations at lowering HA1c levels?

Which patients with T2D will be the most appropriate candidates for the fixed ratio, combination regimens, i.e., iGlarLixi or iDegLira? And just how effective, tolerable, and safe are these formulations at lowering HA1c levels?

How were trials designed that evaluated the effectiveness and safety of the fixed ratio combination of insulin glargine and lixisenatide, and what did we learn about titration and mitigating side effects? Video

How were trials designed that evaluated the effectiveness and safety of the fixed ratio combination of insulin glargine and lixisenatide, and what did we learn about titration and mitigating side effects?

How were the trials designed that evaluated the effectiveness and safety of the fixed ratio combination of insulin glargine and lixisenatide, and what did we learn about titration strategies and mitigating side effects of each components?